Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 478

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 478
---
million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the

NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of € 2,154million on Eloctate franchise products following FDA

approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of € 1,586million on intangible assets relating to SAR444245 (non-

alpha interleukin-2).

(e) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.

(f) See note D.27 .

(g) See note D.28.

(h) 2022 business operating income has been recast from the amount previously reported to include the one-time income of € 952 million from the Libtayo

transaction (€ 706million net of tax) .

D.35.2. Other segment information Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets. The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH & Co. Höchst KG (see Note D.6.).

| SANOFIFORM 20-F2024 | F-97 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.

|                                                      | Biopharma |       |       |
| (€ million)                                          |      2024 |  2023 |  2022 |
| Investments accounted for using the equity method(a) |       234 |   234 |   248 |
| Acquisitions of property, plant and equipment        |     1,733 | 1,619 | 1,529 |
| Acquisitions of other intangible assets              |     1,462 | 1,287 |   574 |

(a) Carrying amount at the end of the reporting period.

D.35.3. Information